CA2046606A1 - Methode d'immobilisation de la cardiolipine, de la phosphatidylcholine et du cholesterol a la phase solide et dosage immunologique - Google Patents

Methode d'immobilisation de la cardiolipine, de la phosphatidylcholine et du cholesterol a la phase solide et dosage immunologique

Info

Publication number: CA2046606A1
Authority: CA; Canada
Prior art keywords: solid phase; antigen; reagent; cardiolipin; composition
Prior art date: 1989-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2046606

Other languages

English (en)

Inventor

Dinesh O. Shah

Rajen C. Gandhi

John A. Todd

Jack Phillips

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxter International Inc

Baxter Healthcare Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-27

Filing date

1990-12-12

Publication date

1991-06-28

1990-12-12 Application filed by Individual filed Critical Individual

1991-06-28 Publication of CA2046606A1 publication Critical patent/CA2046606A1/fr

Status Abandoned legal-status Critical Current

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 66
235000012000 cholesterol Nutrition 0.000 title claims abstract description 33
238000000034 method Methods 0.000 title claims abstract description 22
239000007790 solid phase Substances 0.000 title claims abstract description 20
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 title claims abstract description 16
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract 13
238000003018 immunoassay Methods 0.000 title description 2
238000002764 solid phase assay Methods 0.000 title 1
238000003556 assay Methods 0.000 claims abstract description 47
210000002966 serum Anatomy 0.000 claims abstract description 14
208000006379 syphilis Diseases 0.000 claims abstract 5
239000003153 chemical reaction reagent Substances 0.000 claims description 25
239000000427 antigen Substances 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 21
108091007433 antigens Proteins 0.000 claims description 21
239000002245 particle Substances 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
229910019142 PO4 Inorganic materials 0.000 claims description 14
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 14
239000010452 phosphate Substances 0.000 claims description 14
239000003599 detergent Substances 0.000 claims description 9
230000005298 paramagnetic effect Effects 0.000 claims description 8
244000309466 calf Species 0.000 claims description 7
239000000872 buffer Substances 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
230000008878 coupling Effects 0.000 claims 6
238000010168 coupling process Methods 0.000 claims 6
238000005859 coupling reaction Methods 0.000 claims 6
239000003795 chemical substances by application Substances 0.000 claims 3
125000000524 functional group Chemical group 0.000 claims 3
239000004816 latex Substances 0.000 claims 3
229920000126 latex Polymers 0.000 claims 3
238000005406 washing Methods 0.000 claims 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
230000004520 agglutination Effects 0.000 claims 2
150000001875 compounds Chemical class 0.000 claims 2
239000000463 material Substances 0.000 claims 2
230000007935 neutral effect Effects 0.000 claims 2
239000003960 organic solvent Substances 0.000 claims 2
238000001179 sorption measurement Methods 0.000 claims 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims 1
SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
229960002685 biotin Drugs 0.000 claims 1
235000020958 biotin Nutrition 0.000 claims 1
239000011616 biotin Substances 0.000 claims 1
238000007385 chemical modification Methods 0.000 claims 1
230000002255 enzymatic effect Effects 0.000 claims 1
230000002285 radioactive effect Effects 0.000 claims 1
229940014800 succinic anhydride Drugs 0.000 claims 1
239000012071 phase Substances 0.000 description 14
238000002965 ELISA Methods 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
229920001213 Polysorbate 20 Polymers 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229910018162 SeO2 Inorganic materials 0.000 description 4
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
229920001109 fluorescent polymer Polymers 0.000 description 3
230000005291 magnetic effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
241000283707 Capra Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 2
101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 2
101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
241000022563 Rema Species 0.000 description 2
102100022441 Sperm surface protein Sp17 Human genes 0.000 description 2
QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101100333868 Homo sapiens EVA1A gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100031798 Protein eva-1 homolog A Human genes 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
101100310674 Tenebrio molitor SP23 gene Proteins 0.000 description 1
241000589886 Treponema Species 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

CA 2046606 1989-12-27 1990-12-12 Methode d'immobilisation de la cardiolipine, de la phosphatidylcholine et du cholesterol a la phase solide et dosage immunologique Abandoned CA2046606A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45746689A	1989-12-27	1989-12-27
US457,466		1989-12-27

Publications (1)

Publication Number	Publication Date
CA2046606A1 true CA2046606A1 (fr)	1991-06-28

Family

ID=23816853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2046606 Abandoned CA2046606A1 (fr)	1989-12-27	1990-12-12	Methode d'immobilisation de la cardiolipine, de la phosphatidylcholine et du cholesterol a la phase solide et dosage immunologique

Country Status (5)

Country	Link
EP (1)	EP0460172A1 (fr)
JP (1)	JPH04503865A (fr)
AU (1)	AU7030991A (fr)
CA (1)	CA2046606A1 (fr)
WO (1)	WO1991010138A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776487A (en) *	1996-04-19	1998-07-07	Pasteur Sanofi Diagnostics	Liposome reagents for immunoassays
US5780319A (en) *	1996-04-19	1998-07-14	Pasteur Sanofi Diagnostics	Immunoassays to detect antiphospholipid antibodies
US6177282B1 (en)	1997-08-12	2001-01-23	Mcintyre John A.	Antigens embedded in thermoplastic
GB0104057D0 (en) *	2001-02-20	2001-04-04	Babraham Inst	Antiphospholipid antibody syndrome
DE10250368A1 (de) *	2002-10-29	2004-05-19	Viramed Biotech Ag	Mittel und Verfahren zur Diagnose einer Treponemainfektion
US8017342B2 (en)	2005-04-18	2011-09-13	Bio-Rad Laboratories, Inc.	Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment
US8148057B2 (en)	2005-06-21	2012-04-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Methods, immunoassays and devices for detection of anti-lipoidal antibodies
BRPI0611866B8 (pt) *	2005-06-21	2021-07-27	The Government Of The Us Secretary Of The Department Of Health And Human Services Centers For Diseas	dispositivo de fluxo lateral de imunoensaio, dispositivo de fluxo direto de imunoensaio, método para detectar anticorpos antilipoidais em um sujeito, método para para diagnosticar sífilis em um sujeito e métodos para imobilizar cardiolipina imunorreativa sobre um substrato microporoso
JP4837743B2 (ja) *	2005-11-18	2011-12-14	アメリカ合衆国	修飾カルジオリピンおよびその使用法
US8778619B2 (en)	2005-11-18	2014-07-15	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oxidized cardiolipin and uses to detect cardiolipin antibodies
WO2007066731A1 (fr) *	2005-12-07	2007-06-14	Sekisui Medical Co., Ltd.	Reactif pour le dosage d'anticorps anti-phospholipides et reactif pour dosage d'anticorps anti-treponema pallidum
JP4629563B2 (ja) *	2005-12-07	2011-02-09	積水メディカル株式会社	抗リン脂質抗体測定試薬
FR2994482B1 (fr) *	2012-08-13	2014-08-22	Repropharm	Composition, procede et trousse de detection du pic preovulatoire de lh
CN107533060B (zh)	2015-03-10	2019-11-05	生物辐射实验室股份有限公司	组合密螺旋体和非密螺旋体梅毒测试
RU2633087C2 (ru) *	2016-03-23	2017-10-11	Сейфаддин Гашим Оглы Марданлы	Стабилизированный кардиолипиновый антиген для реакции микропреципитации при диагностике сифилиса и способ его получения
WO2018000381A2 (fr) *	2016-06-30	2018-01-04	深圳市亚辉龙生物科技股份有限公司	Nanobilles revêtues de cardiolipine modifiées et leur procédé de préparation
WO2018000339A1 (fr) *	2016-06-30	2018-01-04	深圳市亚辉龙生物科技股份有限公司	Nanobille magnétique enduite de cardiolipine modifiée et son procédé de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3564089A (en) *	1966-09-29	1971-02-16	Sandra Jean Kiddy	Diagnostic reagent for syphilis
US4738932A (en) *	1985-12-03	1988-04-19	Advanced Polymer Systems, Inc.	Reaginic test for syphilis
JP2736467B2 (ja) *	1987-10-26	1998-04-02	デイド、インターナショナル、インコーポレイテッド	磁気応答ポリマー粒子の製造法およびその応用

1990
- 1990-12-12 AU AU70309/91A patent/AU7030991A/en not_active Abandoned
- 1990-12-12 WO PCT/US1990/007368 patent/WO1991010138A1/fr not_active Ceased
- 1990-12-12 JP JP91501978A patent/JPH04503865A/ja active Pending
- 1990-12-12 EP EP91901576A patent/EP0460172A1/fr not_active Withdrawn
- 1990-12-12 CA CA 2046606 patent/CA2046606A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
AU7030991A (en)	1991-07-24
EP0460172A4 (fr)	1991-10-01
WO1991010138A1 (fr)	1991-07-11
EP0460172A1 (fr)	1991-12-11
JPH04503865A (ja)	1992-07-09

Legal Events

Date	Code	Title	Description
1994-06-12	FZDE	Dead

Publication	Publication Date	Title
EP0267317A1 (fr)	1988-05-18	Procédé pour la détection des protéines et virus
CA1308349C (fr)	1992-10-06	Dosage immunologique et trousse pour la determination d'une espece immunitaire multivaleute a l'aide d'une solution de lavage a base de sel tamponne
EP1049808B1 (fr)	2006-11-22	Detection utilisant la differentiation de force
CA1264662A (fr)	1990-01-23	Methode de dosage au moyen d'immunoliposomes et produits utilises a cette fin
US4738932A (en)	1988-04-19	Reaginic test for syphilis
Richardson et al.	2001	The use of coated paramagnetic particles as a physical label in a magneto-immunoassay
US5145784A (en)	1992-09-08	Double capture assay method employing a capillary flow device
JP3330604B2 (ja)	2002-09-30	固相免疫学的検定法
US4060597A (en)	1977-11-29	Serological reagent and preparation thereof
JPH0296567A (ja)	1990-04-09	アクリジニウムエステルおよびリポソームを用いる分析物検出法
US4707453A (en)	1987-11-17	Vesicle including a metal marker for use in an assay
EP0460172A4 (fr)	1991-10-01	Procede d'immobilisation de cardiolipine, de phosphatidylcholine et de cholesterol en phase solide et immunoanalyse.
US20210018521A1 (en)	2021-01-21	Method for measuring uptake performance of lipoprotein
RU2244933C2 (ru)	2005-01-20	Антигенная композиция и способ обнаружения присутствия treponema pallidum у человека
US20160327555A1 (en)	2016-11-10	Method for avoiding influence of endogenous lipoprotein and reagent
JP2003528289A (ja)	2003-09-24	磁性粒子の二重屈折の緩和の測定を利用する結合反応を検出するための方法
EP3608671A1 (fr)	2020-02-12	Procédé de détection d'analyte
ES2575902T3 (es)	2016-07-04	Potenciador de quimioluminiscencia
JPH0467916B2 (fr)	1992-10-29
US20050282237A1 (en)	2005-12-22	Immunological analysis carrier and an immunological analysis method using the same
CA1039648A (fr)	1978-10-03	Technique de depistage visuel de la syphilis et d'autres maladies a treponeme
EP2653867A1 (fr)	2013-10-23	Biotraceur et son utilisation dans un dosage immunologique
JPH01500848A (ja)	1989-03-23	免疫リポソ−ム定量法−方法と材料
CA1290247C (fr)	1991-10-08	Methode de detection des proteines et des virus
EP4246147B1 (fr)	2026-05-06	Procédé de mesure de stérol dans une lipoprotéine et réactif de mesure de stérol dans une lipoprotéine